Boc-L-Tyr(2,6-Cl2-Bzl)-OH

Boc-L-Tyr(2,6-Cl2-Bzl)-OH is a Boc-protected L-tyrosine derivative bearing a 2,6-dichlorobenzyl-protected phenolic side chain, designed for controlled incorporation of a halogenated tyrosine motif into peptide sequences. The combination of a carbamate N-protecting group and a benzylic phenol protecting group supports standard peptide assembly workflows while maintaining side-chain protection during coupling and deprotection steps. This reagent is commonly selected when downstream targets require a sterically shielded, electronically modified tyrosine side chain for SAR studies, peptide library synthesis, or intermediate preparation for more complex constructs.

1. Solid-Phase Peptide Synthesis

Boc-L-Tyr(2,6-Cl2-Bzl)-OH is used as a protected tyrosine building block in solid-phase peptide synthesis workflows where the phenolic oxygen must remain masked throughout chain assembly. Peptide synthesis teams choose the Boc/2,6-dichlorobenzyl protection pattern to minimize side reactions from the tyrosine hydroxyl while preserving the integrity of the halogenated aromatic side chain. The reagent is particularly relevant for preparing peptides that carry a defined 2,6-dichloro substitution on the tyrosine ring, such as analog panels used in structure-activity relationship studies and peptide property optimization campaigns.

2. Peptide Library SAR Building Blocks

Boc-L-Tyr(2,6-Cl2-Bzl)-OH supports parallel synthesis of tyrosine-containing peptide libraries where controlled side-chain electronics and sterics are required to probe sequence-dependent behavior. Medicinal chemistry groups and peptide discovery teams use this derivative to generate analogs that maintain a protected phenolic handle during assembly, enabling consistent comparison across variants that differ at other positions. The halogenated benzyl-protected tyrosine motif is also valuable for producing chemically defined intermediates that can later be processed to match target peptide specifications, including constructs where the tyrosine side chain is a key variable.

3. Pharmaceutical Intermediate Development

Boc-L-Tyr(2,6-Cl2-Bzl)-OH is employed in the development of peptide-based pharmaceutical intermediates and advanced synthetic fragments that incorporate a protected, halogenated tyrosine side chain. Process and synthesis development teams use this type of protected amino acid to manage functional-group compatibility across multi-step routes, ensuring that the tyrosine phenol does not interfere with coupling chemistry or purification steps during intermediate construction. The reagent's protection scheme makes it a practical choice for assembling larger protected segments and for preparing well-defined inputs for subsequent deprotection and final assembly stages in custom peptide manufacturing research.

4. Halogenated Tyrosine Analog Synthesis

Boc-L-Tyr(2,6-Cl2-Bzl)-OH is used to access halogenated tyrosine analogs in peptide and peptidomimetic synthesis programs that require a specific 2,6-dichloro aromatic pattern. Chemical biology and medicinal chemistry groups select this building block when the tyrosine side chain is expected to influence conformation, aromatic interactions, or local chemical environment in a way that can be systematically studied across analogs. By keeping the phenolic oxygen protected as a benzyl ether during assembly, the reagent helps maintain reproducible synthetic outcomes for constructs where the halogenated tyrosine unit is a defining structural element.

1. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

2. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet

3. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

4. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy